Hitomi Sumiyoshi Okuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hitomi Sumiyoshi Okuma has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Kan Yonemori
National Cancer Center Hospital, Tokyo, Japan
128 shared publications - Akihiro Hirakawa
Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan
124 shared publications - Kenichi Nakamura
National Cancer Center Hospital, Tokyo, Japan
123 shared publications - Kazuki Sudo
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
122 shared publications - Tatsunori Shimoi
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
122 shared publications - Ryo Sadachi
Biostatistics Section, Clinical Research Support Office, National Cancer Center Hospital/Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan
120 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)
Purpose: Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors. Patients and Methods: In this open-label, multicenter phase II study, patients with advanced ALK-altered solid tumors received alectinib (capsule or suspension). The primary endpoint was centrally confirmed objective response rate (ORR) per RECIST v1.1, evaluated using a Bayesian design (expected ORR, 40%; threshold, 10%) in patients receiving intact capsules (cohort A). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Twenty-six patients (age, 8 months–78 years) with 11 tumor types were enrolled; inflammatory myofibroblastic tumor (IMT; n = 9) and neuroblastoma (n = 5) were the most common. ALK alterations included fusions/rearrangements (n = 19), mutations (n = 5), and amplifications (n = 2). The median follow-up was 15 months. In cohort A (n = 16 with measurable disease), the centrally reviewed ORR was 43.8%, meeting the primary endpoint. Among evaluable patients (n = 24), the ORR was 54.2%, and the DCR was 75%. The median PFS and OS were 24.9 and 38.8 months, respectively. Patients with ALK fusions/rearrangements (n = 17) had ORR and DCR of 76.5% and 88.2%, respectively. All patients with IMT achieved tumor shrinkage (ORR, 87.5%). Patients ≤15 years (n = 11) had ORR and DCR of 63.6% and 100%, respectively. Grade ≥3 treatment-related adverse events occurred in 15.4% (n = 4), with no treatment-related deaths. Conclusions: Alectinib demonstrated meaningful, durable responses with acceptable safety across ALK-altered solid tumors, particularly in patients with ALK fusions, supporting further tumor-agnostic development.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Open AccessEfficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)
Purpose: Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors. Patients and Methods: In this open-label, multicenter phase II study, patients with advanced ALK-altered solid tumors received alectinib (capsule or suspension). The primary endpoint was centrally confirmed objective response rate (ORR) per RECIST v1.1, evaluated using a Bayesian design (expected ORR, 40%; threshold, 10%) in patients receiving intact capsules (cohort A). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Twenty-six patients (age, 8 months–78 years) with 11 tumor types were enrolled; inflammatory myofibroblastic tumor (IMT; n = 9) and neuroblastoma (n = 5) were the most common. ALK alterations included fusions/rearrangements (n = 19), mutations (n = 5), and amplifications (n = 2). The median follow-up was 15 months. In cohort A (n = 16 with measurable disease), the centrally reviewed ORR was 43.8%, meeting the primary endpoint. Among evaluable patients (n = 24), the ORR was 54.2%, and the DCR was 75%. The median PFS and OS were 24.9 and 38.8 months, respectively. Patients with ALK fusions/rearrangements (n = 17) had ORR and DCR of 76.5% and 88.2%, respectively. All patients with IMT achieved tumor shrinkage (ORR, 87.5%). Patients ≤15 years (n = 11) had ORR and DCR of 63.6% and 100%, respectively. Grade ≥3 treatment-related adverse events occurred in 15.4% (n = 4), with no treatment-related deaths. Conclusions: Alectinib demonstrated meaningful, durable responses with acceptable safety across ALK-altered solid tumors, particularly in patients with ALK fusions, supporting further tumor-agnostic development.
- Open Access
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2500907
Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis
PURPOSE: Rare cancers are molecularly heterogeneous and lack robust clinical evidence to guide treatment. Whether cancer driver gene expression is governed by tumor lineage or specific somatic alterations—and whether this distinction carries clinical relevance—remains poorly characterized, particularly in Asian populations. This study aimed to determine the relative contributions of tumor lineage and DNA mutations to RNA expression of cancer driver genes and to evaluate the clinical implications of genomic alteration status in Asian patients with rare cancers. METHODS: DNA and RNA were extracted from formalin-fixed paraffin-embedded tumor samples obtained through the MASTER KEY Asia research network. Next-generation sequencing was performed to evaluate genomic alterations and gene expression profiles. RNA expression of cancer driver genes was quantified as TPM Z scores. Elastic net regression with 10-fold cross-validation assessed the relative contributions of tumor lineage and DNA mutations to RNA expression, and findings were independently replicated in another cohort. RESULTS: Integrated DNA and RNA data were available for 128 patients. Tumor lineage was the predominant determinant of RNA expression in 17 of 27 cancer driver genes (63%), whereas ERBB2 and MDM2 demonstrated genomic-predominant regulation, replicated across both cohorts. Alterations in ERBB2 or ARID1A were associated with a lower frequency of disease progression compared with patients without either alteration ( P = .01), independently of ERBB2 RNA expression. Functional subclassification of TP53 revealed that gain-of-function mutations were associated with higher rates of disease progression ( P = .007) and shorter progression-free survival than loss-of-function variants (hazard ratio, 2.355 [95% CI, 1.086 to 5.105]; P = .029). Tumor mutational burden was not associated with treatment response. CONCLUSION: These findings demonstrate that genomic alteration status, including TP53 functional subclassification, provides clinically meaningful information beyond transcriptional profiling alone, supporting integrative genomics and transcriptomics analysis for precision oncology in rare cancers.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (6) , e2500907
Open AccessIntegrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis
PURPOSE: Rare cancers are molecularly heterogeneous and lack robust clinical evidence to guide treatment. Whether cancer driver gene expression is governed by tumor lineage or specific somatic alterations—and whether this distinction carries clinical relevance—remains poorly characterized, particularly in Asian populations. This study aimed to determine the relative contributions of tumor lineage and DNA mutations to RNA expression of cancer driver genes and to evaluate the clinical implications of genomic alteration status in Asian patients with rare cancers. METHODS: DNA and RNA were extracted from formalin-fixed paraffin-embedded tumor samples obtained through the MASTER KEY Asia research network. Next-generation sequencing was performed to evaluate genomic alterations and gene expression profiles. RNA expression of cancer driver genes was quantified as TPM Z scores. Elastic net regression with 10-fold cross-validation assessed the relative contributions of tumor lineage and DNA mutations to RNA expression, and findings were independently replicated in another cohort. RESULTS: Integrated DNA and RNA data were available for 128 patients. Tumor lineage was the predominant determinant of RNA expression in 17 of 27 cancer driver genes (63%), whereas ERBB2 and MDM2 demonstrated genomic-predominant regulation, replicated across both cohorts. Alterations in ERBB2 or ARID1A were associated with a lower frequency of disease progression compared with patients without either alteration ( P = .01), independently of ERBB2 RNA expression. Functional subclassification of TP53 revealed that gain-of-function mutations were associated with higher rates of disease progression ( P = .007) and shorter progression-free survival than loss-of-function variants (hazard ratio, 2.355 [95% CI, 1.086 to 5.105]; P = .029). Tumor mutational burden was not associated with treatment response. CONCLUSION: These findings demonstrate that genomic alteration status, including TP53 functional subclassification, provides clinically meaningful information beyond transcriptional profiling alone, supporting integrative genomics and transcriptomics analysis for precision oncology in rare cancers.
- Open Access
- 14 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis
- 14 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessSustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- Open Access
- 4 February 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (5) , 577-586
Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project
Background: Efficacy of available treatments for liposarcoma (LPS), including dedifferentiated liposarcoma (DDLPS) is limited, and detailed real-world clinical data for patients with LPS treated in Japan are scarce. We used the MASTER KEY Registry Database to evaluate the clinical characteristics and outcomes of patients with advanced/metastatic LPS treated with systemic antineoplastic therapy in Japan. Methods: This non-interventional/observational cohort study included patients with LPS, including DDLPS, and well-differentiated LPS (WDLPS), and a history of systemic antineoplastic therapy, enrolled in the MASTER KEY Project Registry Database from 1 May 2017 to 31 December 2022. Outcomes were analysed by type of treatment. Primary outcomes: progression-free survival (PFS); overall survival (OS). Secondary outcomes: overall response rate; disease control rate. Sensitivity analyses (prospective registry subgroup) were performed to minimize immortal time bias. Results: Since 2017, 100 patients with LPS were prospectively enrolled in the database; of these, 62 had DDLPS and 11 had WDLPS. In patients with LPS, median PFS was 11.1 months after first-line (1 L) pharmacotherapy and 6.9 months after 1 L doxorubicin. In patients with DDLPS, median PFS was 6.9 months after 1 L pharmacotherapy and 4.4 months after 1 L doxorubicin. Median OS after 1 L pharmacotherapy was 45.8 months in patients with LPS, and 40.7 months in those with DDLPS. Median OS in the sensitivity analysis was not reached for patients with LPS and was 13.9 months for the DDLPS subgroup. Conclusions: These data investigating DDLPS in Japanese patients highlight the poor outcomes and lack of effective treatment options in the real-world clinical practice setting.
- 4 February 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (5) , 577-586
Open AccessReal-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project
Background: Efficacy of available treatments for liposarcoma (LPS), including dedifferentiated liposarcoma (DDLPS) is limited, and detailed real-world clinical data for patients with LPS treated in Japan are scarce. We used the MASTER KEY Registry Database to evaluate the clinical characteristics and outcomes of patients with advanced/metastatic LPS treated with systemic antineoplastic therapy in Japan. Methods: This non-interventional/observational cohort study included patients with LPS, including DDLPS, and well-differentiated LPS (WDLPS), and a history of systemic antineoplastic therapy, enrolled in the MASTER KEY Project Registry Database from 1 May 2017 to 31 December 2022. Outcomes were analysed by type of treatment. Primary outcomes: progression-free survival (PFS); overall survival (OS). Secondary outcomes: overall response rate; disease control rate. Sensitivity analyses (prospective registry subgroup) were performed to minimize immortal time bias. Results: Since 2017, 100 patients with LPS were prospectively enrolled in the database; of these, 62 had DDLPS and 11 had WDLPS. In patients with LPS, median PFS was 11.1 months after first-line (1 L) pharmacotherapy and 6.9 months after 1 L doxorubicin. In patients with DDLPS, median PFS was 6.9 months after 1 L pharmacotherapy and 4.4 months after 1 L doxorubicin. Median OS after 1 L pharmacotherapy was 45.8 months in patients with LPS, and 40.7 months in those with DDLPS. Median OS in the sensitivity analysis was not reached for patients with LPS and was 13.9 months for the DDLPS subgroup. Conclusions: These data investigating DDLPS in Japanese patients highlight the poor outcomes and lack of effective treatment options in the real-world clinical practice setting.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 677-685
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 677-685
Open AccessAcquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Criteria for modifying treatment
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Criteria for modifying treatment
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Targeted sequencing analysis of cell-free DNA samples
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Targeted sequencing analysis of cell-free DNA samples